Somerville, Mass.-based Mass General Brigham has spun off AI startup Aevius, which launched Nov. 17 with $22 million in seed funding led by software investor Insight Partners.
Aevius builds AI models that learn from a patient’s full medical history. Its models combine clinical notes, imaging, biomarkers and other data into a continuously updated, computable representation of each patient. Organizations can use it to forecast outcomes, find clinically similar patients, stratify populations and monitor change over time.
The company is selling the technology to health systems, payers and life sciences companies. For health systems, Aevius said the technology could help predict disease progression, identify patients at risk of complications and personalize care.
The funding will go toward model and product development, hiring across engineering, clinical and commercial teams, and commercial deployment.
Aevius was founded by Rowland Pettit, MD, PhD; Ming Yang “Max” Lu, PhD; Faisal Mahmood, PhD; and Long Phi Le. All four were part of the founding team behind Modella AI, which AstraZeneca acquired. Dr. Pettit serves as CEO, and Dr. Lu serves as CTO. Eric Topol, MD, chairs the company’s scientific advisory board.
“Our mission is to make medicine computable,” Dr. Pettit said.
Chris Coburn, chief innovation officer at Mass General Brigham, said the health system “develops AI with the ambition to improve healthcare far beyond our own hospitals.” Mr. Coburn said the spinout combines research developed at Mass General Brigham with a team experienced in bringing medical AI to market.
Insight Partners has more than $90 billion in regulatory assets under management and has invested in more than 900 companies.